相关实验视频

Updated: Jul 19, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

PTEN和P-4E-BP1可能与同时接受放射化疗的直肠癌患者的术后复发有关

Heng Zhang¹, Xiaofan Li², Wanjun Sun¹

¹Department of Oncology, Tianjin Union Medical Center, Nankai University, No.190 Jieyuan Road, Hongqiao District, Tianjin, 300121, P. R. China.

|May 13, 2024

概括

发现局部晚期直肠癌 (LARC) 的生物标志物至关重要. PTEN和p-4E-BP1在预测手术和放射化疗后复发方面表现有希望,有助于个性化治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
手术瘤学手术瘤学

背景情况:

局部复发显著影响局部晚期直肠癌 (LARC) 患者在手术后和放射化疗后的预后.
识别放射化疗敏感性的分子标记是个性化癌症治疗的关键.

研究的目的:

为了确定潜在的瘤生物标志物来预测LARC患者的术后复发.
评估PTEN,SIRT1,p-4E-BP1和ps6在局部复发中的作用.

主要方法:

对接受手术和同时接受放射化疗的LARC患者的回顾性分析.
对PTEN,SIRT1,p-4E-BP1和ps6蛋白表达的免疫组织化学评估.
具有和没有局部复发的患者之间的蛋白质表达的比较.

主要成果:

在没有局部复发的患者中观察到较高的PTEN表达和较低的p-4E-BP1表达.
TNM阶段,淋巴血管入侵 (LVI),PTEN和p-4E-BP1被确定为局部复发的独立风险因素.
PTEN和p-4E-BP1表达的显著差异与复发状态相关.

结论:

在LARC中,PTEN和p-4E-BP1可以作为有价值的生物标志物用于预后预测.
这些蛋白质代表了改善LARC患者治疗结果的潜在治疗点.
需要进一步的研究来验证这些发现,并探索治疗应用.

关键词:

在 4E-BP1 中.同时进行放射化疗.当地复发局部复发在这里,我们可以使用PTEN.这是直肠癌.

更多相关视频

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...